Sunovion Presents Phase III Data Showing Safety, Efficacy And Improvement In Quality Of Life Outcomes In Patients With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease Treated With SUN-101/Eflow (Glycopyrrolate)
5/23/2017 COPD, Sumitomo Dainippon, Overseas, Respiratory
5/23/2017 COPD, Sumitomo Dainippon, Overseas, Respiratory
- 大日本住友製薬の米国子会社SunovionがCOPD（慢性気道閉塞疾患）治療薬として申請中のムスカリン拮抗薬SUN-101/EflowのP3成績を米国胸部学会で発表した。